Fullness of fat storage capacity: An alternative to adipocyte insulin resistance

Journal of Applied Research

Volumn 1, Issue 1, 2001, Pages

  Poothullil, John M ^a  

^a Brazosport Memorial Hospital   (United States)

Author keywords

Adipocyte insulin resistance; Fat stores; Insulin resistance; Obesity; Type 2 diabetes

Indexed keywords

EID: 33646025200     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Golay A, Swislocki ALM, Chen Y-D I, Reaven GM: Relationships between plasma-free fatty acid concentration, endogenous glucose production, and fasting hyperglycemia in normal and non-insulin-dependent diabetic individuals. Metabolism 36:692-696, 1987.
2. Fraze E, Donner CC, Swislocki ALM, et al: Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: Evidence for insulin resistance. J Clin Endocrinol Metab 61:807-811, 1985.
3. Golay A, Felber JP, Jequier E, et al: Metabolic basis of obesity and noninsulin-dependent diabetes mellitus. Diabetes Metab Rev 4:727-747, 1988,
4. Chen Y-DI, Golay A, Swislocki LM, Reaven GM: Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin dependent diabetes mellitus. J Clin Endocrinol Metah 64:17-21, 1987.
5. Skowronski R, Hollenbeck CB, Varasteh BB, et al: Regulation of non-esterified fatty acid and glycerol concentration by insulin in normal individuals and patients with type 2 diabetes. Diabetic Med 8:330-333, 1991.
6. Hardy RW, Ladenson JH, Henriksen EJ, et al: Palmitate stimulates glucose transport in rat adipocytes by a mechanism involving translocation of the insulin sensitive glucose transporter (GLUT 4). Biochem Biophys Res Commun 177:343-349, 1991.
7. Saggerson ED: The regulation of glyceride synthesis in isolated white-fat cells. The effects of palmitate and lipolytic agents. Biochem J 128:1057-1067, 1972.
8. Hunnicutt JW, Hardy RW, Williford J, McDonald JM: Saturated fatty acid-induced insulin resistance in rat adipocytes. Diabetes 43:40-45, 1994.
9. Epps-Fung MV, Williford J, Wells A, Hardy RW: Fatty acid-induced insulin resistance in adipocytes. Endocrinology 138:4338-4345, 1997.
10. Hotamisligil GS: The role of TNF alpha and TNF receptors in obesity and insulin resistance. J Intern Med 245:621-625, 1999.
11. Hotamisligil GS: Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 107:119-125, 1999.
12. Garvey WT, Huecksteadt TP, Matthaei S, Olefsky JM: Role of glucose transporters in the cellular insulin resistance of type II non-insulin-dependent diabetes mellitus. J Clin Invest 81; 1528-1536, 1988.
13. Kolterman OG, Gray RS, Griffin J, et al: Receptor and post receptor defects contribute to the insulin resistance in Noninsulin-Dependent diabetes mellitus. J Clin Invest 68:957-969, 1981.
14. Bonnet FP: Fat cell size and number in obese children, in Bonnet FP (ed): Adipose Tissue in Childhood. Boca Raton, FL, CRC, 1981, p 133-154.
15. Brook CGD, Lloyd JK, Wolf WO: Relation between age of onset of obesity and size and number of adipose cells. Br Med J 2:25-27, 1972.
16. Faust IM: Role of the fat cell in energy balance physiology, in Stunkard AJ, Stellar E (eds): Eating and Its Disorders. New York, Raven, 1984, p 97-107.
17. Shillabeer G, Forden JM, Lau DCW: Induction of preadipocyte differentiation by mature fat cells in the rat. J Clin Invest 84:381-387, 1989.
18. Hausman GJ, Wright JT, Dean R, Richardson RL: Cellular and molecular aspects of the regulation of adipogenesis. J Anim Sci 71(Suppl 2):33-55, 1993.
19. Marques BG, Hausman DB, Martin RJ: Association of fat cell size and paracrine growth factors in development of hyperplastic obesity. Am J Physiol 275:R1898-R1908, 1998.
20. Prins JB, O'Rahilly S: Regulation of adipose cell number in man. Clin Sci 92:3-11, 1997.
21. Deslex S, Negrel R, Vannier C, et al: Differentiation of human adipocyte precursors in a chemically defined serum-free medium. Int J Obes 10:19-27, 1986.
22. Entenmann G, Hauner H: Relationship between replication and differentiation in cultured human adipocyte precursor cells. Am J Physiol Cell Physiol 270:C1011-C1016, 1996.
23. Kirkland JL, Hollenberg CH, Gillon WS: Age, anatomic site, and the replication and differentiation of adipocyte precursors. Am J Physiol Cell Physiol 258:C206-C210, 1990.
24. Salans LB, Knittle JL, Hirsch J: The role of adipose cell size and adipose tissue insulin sensitivity in the carbohydrate intolerance of human obesity. J Clin Invest 41: 153-165, 1968.
25. Phillips SM, Han XX, Green HJ, et al: Increments in skeletal muscle GLUT-1 and GLUT-4 after endurance training in humans. Am J Physiol 270(3 Pt1):E451-E462, 1996.
26. Houmard JA, Shinebarger MH, Dolan PL, et al: Exercise training increases GLUT-4 protein concentration in previously sedentary middle-aged men. Am J Physiol 264 (6 Pt1): E896-E901, 1993.
27. Hughes VA, Fiatarone MA, Fielding RA, et al: Exercise increases muscle GLUT-4 levels and insulin action in subjects with impaired glucose tolerance. Am J Physiol 264(6 Pt 1):E855-E862, 1993.
28. Dela F, Ploug T, Handberg A, et al: Physical training increases muscle GLUT4 protein and mRNA in patients with NIDDM. Diabetes 43:862-865, 1994.
29. Karnieli E, Zarnowski MJ, Hissin PJ, et al: Insulin-stimulated translocation of glucose transport systems in the isolated rat adipose cell. J Biol Chem 256(10):4772-4777, 1981.
30. Suzuki K, Kono T: Evidence that insulin causes translocation of glucose transport activity to the plasma membrane from an intracellular storage site. Proc Natl Acad Sci USA77(5):2542-2545, 1980.
31. Garvey WT, Maianu L, Huecksteadt TP, et al: Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulindependent diabetes mellitus and obesity. J Clin Invest 87:1072-1081, 1991.
32. Tirosh A, Rudich A, Bashan N: Regulation of glucose transporters-Implications for insulin resistance states. J Pediatr Endocrin Metab 13:115-133, 2000.
33. Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-891, 1963.
34. Groop LC, Saloranta C, Shank M, et al: The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Endocrinol Metab 72(1):96-107, 1991.
35. Bonadonna RC, Groop LC, Zych K, et al: Dose-dependent effect of insulin on plasma free fatty acid turnover oxidation in humans. Am J Physiol 259(Endocrinol Metab 22):E736-E750, 1990.
36. Boden G, Jadali F, White J, et al: Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest 88:960-966, 1991.
37. Randle PJ, Newsholme EA, Garland PB: Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketonebodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J 93:652-665, 1964.
38. Thiebaud D, DeFronzo Ra, Jacot E, et al: Effect of long chain triglyceride infusion on glucose metabolism in man. Metabolism 31:1128-1136, 1982.
39. Felley CP, Felley EM, van Meile GD, et al: Impairment of glucose disposal by infusion of triglycerides in humans: Role of glycemia. Am J Physiol 256:E747-E752, 1989.
40. Wolfe B, Klein MS, Peters EJ, et al: Effect of elevated free fatty acids on glucose oxidation in normal humans. Metabolism 37:323-329, 1988.
41. Foley JE: Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care 15:773-784, 1992.
42. Unger RH: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: Genetic and clinical implications. Diabetes 44:863-870, 1995.
43. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10, 1997.
44. Steppan CM, Bailey ST, Bhat S, et al: The hormone resistin links obesity to diabetes. Nature 409:307-312, 2001.
45. Friedman JM, Halaas JL: Leptin and the regulation of body weight in mammals. Nature 395:763-770, 1998.
46. Peiris AN, Mueller RA, Smith GA, et al: Splanchnic insulin metabolism in obesity: Influence of body fat distribution. J Clin Invest 78:1648-1657, 1986.
47. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U: Impact of obesity on metabolism in men and women. J Clin Invest 72:1150-1162, 1983.
48. Boden G, Chen X, Ruiz J, et al: Mechanisms of fatty acid induced inhibition of glucose uptake. J Clin Invest 93:2438-2446, 1994.
49. Boden G, Chen X: Effects of fat on glucose uptake and utilization in patients with noninsulin-dependent diabetes. J Clin Invest 96:1261-1268, 1995.
50. Kolaczynski JW, Boden G: Effects of oleate and fatty acids from omental adipocytes on insulin uptake in rat liver cells. Endocrinology 133:2871-2874, 1993.
51. Schoonjans K, Stals B, Auwerz J: The peroxisome proliferator activated receptor and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302:93-109, 1996.
52. Wahli W, Braissant O, Desvergne B: PPARs: A nuclear signaling pathway in lipid metabolism. Anna Rev Cell Dev Biol 12:335-363, 1996.
53. Spiegelman BM, Flier JS: Adipogenesis and obesity: Rounding out the big picture. Cell 87:377-389, 1996.
54. Lefebvre AM, Laville M, Vega N, et al: Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 47:98-103, 1998.
55. Forman BM, Tontonoz P, Chen J, et al: 15-Deoxy- 12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARr. Cell 83:803-812, 1995.
56. Lehman JM, Moore LB, Smith-Oliver TA, et al: An antidiabetic Thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor r (PPARr). J Biol Chem 270:12953-12956, 1995.
57. Akazawa H, Kawasaki E, Sun F, et al: Efficacy of Troglitazone on Body Fat Distribution in Type 2 Diabetes. Diabetes Care 23:1067-1071, 2000.
58. Adams M, Montague CT, Prins JB, et al: Activators of peroxisome proliferator-activated receptor y have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153, 1997.
59. Kelly IE, Walsh K, Han TS, Lean MJ: Effect of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22:288-293, 1999.
60. Suter SL, Nolan JJ, Wallace P, et al: Metabolic effects of new oral hypoglycemie agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992.
61. Fuchtenbusch M, Standl E, Schatz H: Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 108 (3): 151-163, 2000.
62. Krentz AJ, Bailey CJ, Melander A: Thiazolidinediones for type 2 diabetes. BMJ 321:252-253,2000.
63. Mori Y, Yokoyama J, Murakawa Y, et al: Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22:908-912, 1999.
64. Brown KK, Henke BR, Blanchard SG, et al: A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 48:1415-1424, 1999.
65. Henry RR, Wallace P, Olefsky JM: Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes 35:990-998, 1986.
66. Olefsky JM, Reaven GM, Farquhar JW: Effects of weight reduction on obesity: Studies of carbohydrate and lipid metabolism in normal and hyperlipoproteinemic subjects. J Clin Invest 53:64-76, 1974.
67. Vague J (ed): Obesities, ed 1. London, John Libbey and Company Ltd, 1991, p 20.
68. Hirsch J: Adipose cellularity in relation to human obesity, in Stollerman GH (ed): Advances in Internal Medicine, vol 17. Chicago, Year Book Medical Publishers, 1971, pp289-300.
69. Groop LC, Tuomi T: Non-insulin-dependent diabetes mellitus-A collision between thrifty genes and an affluent society. Ann Med29(1):37-53, 1997.
70. Dorfler H, Rauh G, Basserman R: Lipoatrophic diabetes. Clin Invest 71:264-269, 1993.
71. Kelly DE, Mandarine LJ: Fuel selection in human skeletal muscle in insulin resistance: A reexamination. Diabetes 49(5):677-683, 2000.